Direct from consumers: A survey of 1,048 customers of three DTC personal genomic testing companies about motivations, attitudes, and responses to testing.

Slides:



Advertisements
Similar presentations
SEM A – Marketing Information Management
Advertisements

Surveys and Questionnaires. How Many People Should I Ask? Ask a lot of people many short questions: Yes/No Likert Scale Ask a smaller number.
Folic Acid and Pregnancy Data from the Pregnancy Risk Assessment Monitoring System (PRAMS)
Newborn Screening: Survey of Parents’ Views and Experiences Robert Clark Clinical Ethics and Law Group Faculty of Medicine University of Southampton.
Health Information Security & Privacy February 9, 2014 ONC Policy HIT Policy Committee Privacy and Security Workgroup Denise Anthony Sociology and ISTS.
Improving health outcomes across England by providing improvement and change expertise How to Measure Patient Activation Measuring Patient Activation In.
Information Seeking Experiences of Cancer Survivors: Frustrated or Satisfied? Whitney Randolph Steele, PhD, MPH Cancer Prevention Fellowship Program Division.
Genetics and Public Policy Center
Managing Marketing Information
Why Are We Here? The History and Landscape of DTC Genetic Tests Elizabeth Mansfield, Ph.D. OIVD/CDRH/FDA March 8, 2011 Molecular and Clinical Genetics.
Consumer Satisfaction Surveys 2009 Survey For further information contact Dennis McBride (253) or For the complete report.
NCHS Data – Strengths and Weaknesses from the NHLBI Perspective Paul Sorlie, Ph.D. Chief, Epidemiology Branch National Heart, Lung, and Blood Institute.
Recent and prospective mothers’ attitudes and preferences regarding newborn genetic screening: a survey of 2,266 U.S. women Secretary's Advisory Committee.
Knowledge of Emergency Contraception in California Recent Trends and Persistent Disparities May 24, 2005 San Francisco, California UNIVERSITY OF CALIFORNIA,
Food Labels and Weight Loss: Evidence from the National Longitudinal Survey of Youth Bidisha Mandal Washington State University AAEA ‘08, Orlando.
Principles of Marketing
Evaluation. Practical Evaluation Michael Quinn Patton.
Methodologic Overview of Two National Data Sets Centers for Disease Control and Prevention National Center for Health Statistics Issues in Comparing Findings.
Direct-to-Consumer Advertising of Prescription Drugs: Looking Back, Looking Forward Kathryn J. Aikin, Ph.D. Division of Drug Marketing, Advertising and.
Think before you spit: ELSI and the Direct-to-Consumer Genetic Testing Space Jan Charbonneau, Dianne Nicol & Don Chalmers Centre for Law & Genetics, University.
Business and Management Research
A Deeper Understanding of Avery Fitness Center Customers
 Abstract For women newly diagnosed with breast cancer, psychosocial distress may interfere with their ability to cope with cancer treatment. Nurses should.
GENETIC TESTING: WHAT DOES IT REALLY TELL YOU? Lori L. Ballinger, MS, CGC Licensed Genetic Counselor University of New Mexico Cancer Center.
Asian American Health Needs Assessment Asian American Health Needs Assessment Phase One: the AsANA survey Beverly J. Gor, EdD, RD, LD, CDE, TruongSon Hoang,
In what ways are our superstitions and beliefs in the supernatural different to Chinese people?  The following is an example to help with your Tangjia.
Cultural Difference: Investment Attitudes and Behaviors of High Income Americans Tahira K. Hira – Iowa State University
Sugar, Heart and Life: A Guide to Living with Diabetes Stephen Spann, MD Department of Family and Community Medicine.
Overview of Phase I Data: Approach and Findings Gary Bess Associates April 15, 2009.
GENOMICS, ACRONYMS, AND UNDERSTANDING: TRANSLATING GENETICS RESEARCH FROM CANCER FAMILY REGISTRIES TO BEHAVIORAL MEDICINE Sherri Sheinfeld Gorin (Chair),
Engaging Vulnerable Consumers in Developing Useful Public Health Care Reports Funding by the Agency for Healthcare Research and Policy (AHRQ) grant number.
Impact Health NDAC Meeting Stewart Levy R.Ph. January 14, 2005.
Should individuals be able to directly access their genetic information without physician involvement? Jeff Gulcher MD PhD Chief Scientific Officer and.
Healthcare Costs in Retirement Consumer Study – February 2012 NFM-10454AO.1.
Quality Through the Eyes of the Patient: State-of-the-Art Concepts Paul D. Cleary, Ph.D. April 10, 2001 Quality Through the Eyes of the Patient: State-of-the-Art.
Southeast Missouri State University: Campus Health Clinic Carly FinkeCory Gool Rachel HofmannDerek Miller Adam KazdaMichael Rhyne Joshua McDonoughBenjamin.
Maryland Department of Health and Mental Hygiene WB&A Market Research Executive Summary THE 2003 MARYLAND MEDICAID MANAGED CARE CUSTOMER SATISFACTION SURVEY.
Director of Evaluation and Accountability Manager, UW’s Grand Rapids, Michigan Robert McKown, CIRS Director of Evaluation and Accountability Sherri.
Mary’s relative risk: below average Mary’s estimated lifetime risk: 25% Mary has 17 of the 36 risk markers Mary’s estimated risk We took the average risk.
1 Patient Communications Presented by: Carol Rothkopf December 7, 2005.
Preparing for an Expanded Medicaid Population under the ACA: Undiagnosed and Untreated Health Needs Sandra Decker, Deliana Kostova, Genevieve Kenney and.
Figure 1. Distribution of Individuals Covered by Private Health Insurance, by Type of Health Plan Comprehensive = health plan with no deductible or
Questionnaires and Interviews Steven R. Cummings, MD Director, S.F. Coordinating Center.
Prepared For: definition, IFSA Conference 2005 By: Linda McAvenna Dissecting the investor psyche: what motivates our clients.
Who’s behind the screen & what are they looking for? Comparing data from the Health Information National Trends Survey, the American Customer Satisfaction.
Tested Messages to Reach the Unscreened 80% by 2018 Forum Mary Doroshenk, MA, NCCRT Director 1.
Designing Survey Instruments. Creating a Survey Instrument  Survey instruments should help researchers collect the most accurate data and reach the most.
1 National Medigap Enrollees Survey Gary A. Ferguson Senior Vice President and Gina Scime Research Analyst N = 500 Medigap Enrollees, Nationwide. April.
The Relationship between Nativity Status, Satisfaction with and Confidence in Health Care Florence J. Dallo, PhD MPH Academy Health Meeting 9 June 2008.
DODAC and DSaRM Advisory Committee August 1, 2007 Pregnancy Registry and Root Cause Analysis Cynthia Kornegay, Ph.D. Division of Drug Risk Evaluation Office.
Bringing it Back to the Patient Leveraging the Use of Data and Technology for Innovative Insights Leading to Patient Engagement and Influence Amy Smalarz,
Scientific Method, Types of Experiments and Data Processing
Financial Capability and Psychosocial Well-Being James Kunz, PhD, Associate Professor, McDaniel College, and Christine Callahan, PhD, LCSW-C, Research.
Margot E. Ackermann, Ph.D. and Erika Jones-Haskins, MSW Homeward  1125 Commerce Rd.  Richmond, VA Acknowledgements The Richmond.
Rationalizing the New Healthcare Paradigm Scientific Agenda vs. Patient Imperatives Scientific Agenda vs. Patient Imperatives.
2010 President Obama signed the Affordable Care Act Small businesses receive health insurance tax credits for providing insurance benefits to workers Providing.
1 DRAFT SLIDES FOR NDA ADVISORY COMMITTEE PRESENTATIONS.
Mr. J. Fletcher ENT 12. Putting the right product in the right place, at the right price, at the right time.
Pivotal Label Comprehension Study Mevacor™ OTC Capt. Laura Shay, RN, MS, C-ANP Division of Over-the-Counter Drug Products Center for Drug Evaluation and.
College Students’ Behaviors, Perceptions, Beliefs, and Attitudes Regarding Tanning Bed Use Fawna M. Playforth, BS; Laurie J. Larkin, PhD; & Laurel A. Mills,
Infant Feeding Practices Study II Methods American Public Health Association November 5, 2007 Sara B. Fein, Judith Labiner-Wolfe, Katherine Shealy, Ruowei.
Student-Run Free Clinics: Analyzing Patients' Willingness to Return Jason Zucker Summer Elshanawy Janet Cruz Robin Schroeder Steven Keller Jason Zucker.
Do Decision Aids Promote Shared Decision-Making for Prostate Cancer Screening? Alex Krist MD Steven Woolf MD MPH Robert Johnson PhD Department of Family.
Study of C.H.I.L.D. G.A.P.S.* *Children’s Health Insurance Lapses and Discontinuities to Gain better Access through Policy Solutions Jennifer DeVoe Alan.
Patient Experiences with Pharmacogenetic Testing in a Primary Care Setting Rachel Mills 1, Jivan Moaddeb 1, Nancy Allen Lapointe 2, Alex Cho 1,3, Shelby.
Student Interest in Genetic Testing for Type 2 Diabetes Mellitus Sajel Shah, Biological Sciences.
Believed discrimination occurred because of their:
Integrating Genetics & Genomics Education into Nursing Workforce
Child Health Evaluation and Research Unit
Presentation transcript:

Direct from consumers: A survey of 1,048 customers of three DTC personal genomic testing companies about motivations, attitudes, and responses to testing Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee, March 8-9, 2011 Dave Kaufman, Ph.D. Genetics and Public Policy Center Johns Hopkins University, Washington, DC Work funded by NHGRI Grant 1R1HG

Several valid concerns about DTC Testing Validity & utility Risks and benefits are not well understood Misleading or unwarranted claims May lead to purchase for the wrong reasons Consumers may be unable to interpret data What will people do with it? Empirical data being collected

DTC consumers’ perspectives Survey of customers of 3 companies 23andMe ($429-$499), Navigenics ($999), deCODEme ($800-$2000) Randomly sampled & contacted by companies 2-8 months after receiving results Online survey, 20 minutes, $10 January - May ,163 of 3,167 invited responded (37%) 1,048 (90%) qualified

Aims of the survey Who is purchasing the tests? Why? What are their overall reactions? Interpretation and understanding What are they doing with the information?

Limitations Cross-sectional survey: no follow-up over time No data on individuals’ specific genes or risks Data from all three companies analyzed in aggregate

DTC Customers (%) US population 18+ (%) Age Women4651 Household Income $0-59, $60,000-84, $85, , $125, Education Attained 0-12 Years years College46 Postgraduate549 Race/Ethnic Group White non-Hispanic8765 Asian/PI (non-Hispanic)54 Black non-Hispanic112 Hispanic315 AI/AN (non-Hispanic)0.51 Other non-Hispanic3.52 Demographics

REASONS FOR TESTING

42% were interested in specific health conditions the company tests for

33% were interested in part because first-degree relative(s) “have been diagnosed with one of the medical conditions included in the service”

How important were the following when you were deciding whether or not to use the company service?

REACTIONS TO TESTING

Satisfaction “How satisfied were you with the [23andMe/deCODEme/Navigenics] service?” Very Satisfied Very Dissatisfied (0.5) Dissatisfied (1.5) Neither

Satisfaction across demographic groups (% who were satisfied or very satisfied)

Overall reactions to the services I satisfied my curiosity I feel there is nothing I can do to change my health risks I have relief from uncertainty about some aspects of my health Agree89% Disagree11% Agree8% Disagree92% Agree49% Disagree51%

Clarity and value of the reports Agree88% Disagree12% Agree38% Disagree62% Agree84% Disagree16% 92% 54% % who were satisfied Reports were easy to understand Felt value of the data was worth the cost Conclusions were too vague

INTERPRETING RESULTS

What participants felt they learned Yes58% No42% Did you learn anything that you could use to improve your health that you did not already know? 96% 76% % who were satisfied

Interpreting the data Participants were shown two hypothetical test results, using the exact format their company utilizes in its reports, and asked to interpret them

Interpreting the data Mary: 25% risk of diabetes Population risk: 30% Mike: 11% risk of colorectal cancer Population risk : 6% “Based on the information above, which answer best describes how Mary’s/Mike’s risk of [disease] compares to the average person’s risk?” MaryMike More likely to get disease 594 Less likely to get disease 903 Has the same risk 42 I don’t know 21

Mary’s diabetes - % with incorrect answer in green Mike’s Colorectal Cancer - % with incorrect in

What do people do based on the data? 28% discussed results with a healthcare prof. Including: 20% with primary health care providers 1% contacted a genetic counselor 19% with other health care professionals 9% followed up with additional laboratory tests

16% changed medication or supplement regimens based on data 10% changed dietary supplements 3% changed OTC medicines 4% changed Rx, in consult with doctor 0.4% changed Rx, without consulting doctor Among those changing one or more regimens, 54% shared results w/ h.c. provider

Behavioral changes as a result -at one point in time! 34% more careful about diet 0.1%less careful 65%the same 14% exercise more 31% “more determined to exercise” nobody exercises less or is less determined

Conclusions Demographics of early DTC customers skewed Curiosity about what might ail you highly valued Satisfaction high, though not among those who found reports difficult

Conclusions Some of what companies try to communicate is understood Whether information given is accurate or valid is a different question Measureable issues with interpretation suggest reports can be improved Behavioral changes observed – could be positive or negative, transient or lasting – Are not the same as outcomes Longitudinal studies w/richer data needed

Thanks to Juli Murphy Kim Kreger Joan Scott Gail Javitt Kathy Hudson Stephanie Devaney Robert Green Sara Katsanis Survey Participants Amy DuRoss Brenna Sweeney Joanna Mountain Amy Keifer Jeffrey Gulcher Jónheiður Ísleifsdóttir Knowledge Networks NIH Navigenics GPPC/JHU 23andMe deCODEme Duke Boston U. Work funded by NHGRI Grant 1R1HG